OregonTherapeutics is developing XCE853 : Disruptive targeted therapy “First in class” & “Best in class” in oncology. XCE853 is based on an innovative and unique mechanism of action : Inhibition of protein disulfide isomerase. OregonTherapeutics first objective is to bring XCE853 into clinical trial (phase 1) for the treatment of cancer within 2 years. Based on the scientific rationale, the priority indication is advanced pancreatic cancer. Potential additional indications are ovarian, livers, and head & neck cancers.